Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF V600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Titel:
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF V600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Auteur:
Dummer, Reinhard Brase, Jan C Garrett, James Campbell, Catarina D Gasal, Eduard Squires, Matthew Gusenleitner, Daniel Santinami, Mario Atkinson, Victoria MandalĂ , Mario Chiarion-Sileni, Vanna Flaherty, Keith Larkin, James Robert, Caroline Kefford, Richard Kirkwood, John M Hauschild, Axel Schadendorf, Dirk Long, Georgina V